News
Novartis drug Tasigna received approval from the European Commission
Novartis received approval from the European Commission for Tasigna® (nilotinib) as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The approval from the European Commission...
News
Arena and Eisai Complete End-of-Review Meeting with FDA
Arena Pharmaceuticals, Inc. and Eisai Inc. announced today the completion of an end-of-review meeting with the US Food and Drug Administration (FDA) for the lorcaserin New Drug Application (NDA). Jack Lief, Arena's President and Chief Executive...
News
Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis
H. Lundbeck A/S announced that it has signed agreements with Zenobia Therapeutics (Zenobia) and Vernalis plc (Vernalis) which will provide Lundbeck with access to know-how relevant for making inhibitors for Leucine-rich repeat kinases. Lundbeck will...
News
Merck Serono and San Raffaele Institute to Collaborate on Research
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced a strategic collaboration with the Institute of Experimental Neurology (INSpe) and the Department of Neurology of the San Raffaele Scientific Institute (Milan, Italy) to advance clinical research projects in...
News
Addex Awarded EuropaBio’s Most Innovative SME Award
Allosteric modulation company Addex Pharmaceuticals announced that the company has been awarded EuropaBio’s Most Innovative SME Award. This is the first time that the award has been presented and it attracted applications by 32 companies from 12 countries representing...
News
Fluxion Biosciences Announces Product Launch of BioFlux 1000Z
Fuxion Biosciences, Inc. announced that the new BioFlux 1000Z system for live cell imaging will be launched at the 50th American Society for Cell Biology Annual Meeting to be held December 11-15, 2010 in Philadelphia, PA. The BioFlux 1000Z...
News
GSK signs agreement to acquire Nanjing MeiRui Pharmaceuticals
GlaxoSmithKline plc announced that it has entered into an agreement to acquire Nanjing MeiRui Pharma Co., Ltd (MeiRui) for a cash consideration of approximately $70 million. Ninety per cent of the share capital of MeiRui is to be acquired...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read